A study published in Nature Microbiology now shows for the first time that Candida auris uses a CO₂-based metabolic strategy to survive in the nutrient-poor conditions of the skin and to better tolerate antifungal therapies – especially amphotericin B (AMB).24. Dezember 2025
Health Abridge and Highmark Collaborate on AI-Powered Prior Authorization Solution –Healthradar12. August 2025 What You Should Know: – Highmark Health announced today the launch of an enterprise-wide collaboration with Abridge to deploy its ambient…
